Winnie To

Establish and expand the end-to-end supply chain capabilities, business processes, global network capacities (suppliers/CMs, warehouse/3PLs, manufacturing sites) to support the company’s revenue growth from $12M to $700M+ from 2018 to 2023. Led SCM efforts to implement the Tier 1 Oracle ERP platform supporting the company's continuous exponential growth to $1B revenue in 2 years.

Managed supply chain and network planning of respiratory, anti-fungal, cardiovascular and oncology products with ~$1.5B in revenue (solid dose tablets, injectables / sterile vials, and device). Oversaw an end-to-end constrained global supply network of 4 internal and 8 contract manufacturing sites distributing products to ~60 countries. Led product supply strategy and cross-functional communications during supply challenges to prevent product shortages.

Created firm’s first supply chain team and established business processes across procurement, planning, inventory management, and data management. Collaborated with finance and legal teams to implement key supplier agreements, pricing contracts, and procurement initiatives with greater than $1.4M savings (2014).

Led supply planning of $1.6B Class II/III bio-surgery product portfolio to meet global direct sales and distribution demands. Collaborated with APAC, LATAM, and EU regions. Improved fulfillment from 76% to 96%, with no material stock out or major interruption to production.

Designed a risk-based Excel model template for client to enable new product investment evaluations. For one of the biotech clients with flagship product $70.2M sales in 2013, $26.2M sales in 2012: • Developed a PTS risk-adjusted discounted cash flow model to evaluate long-term financial impact of patient/market expansion of flagship product to facilitate investment decisions. Modeling parameters include: WW revenue forecast, development timeline, development costs, milestone and royalty payments, commercial costs, probability of Phase 3 and regulatory approval successes, probability of competitor entry timeline.

Delivered NPV and strategic analysis, supporting business case development of ~30 Technical Research and Development innovation and technology proposals; drove strategic long-term recommendations, and short-term actions. Mentored 3 high-performing rotational program associates.

Developed formulations and commercially scalable processes for new oral solid dose (OSD) drug products from early-stage development to registration phases. Oversaw manufacture of critical cGMP clinical production activities to meet project timelines. Led development efforts of Jurnista program that contributed to EU launch ($145M WW sales in 2012). Co-inventor of 3 patient applications and authored 36 technical reports supporting IND/NDA filings. Mentored 4 co-op students.

• National Dean's List

• Honors in Advanced International Management • Net Impact Consulting Challenge - 1st place

• Tau Beta Pi Engineering Honor Society • Dean's List, various scholarships, awards and fellowships recipient • Certificate of Management Studies in Accounting / Finance